-
July 1, 2024
Aileron Therapeutics to be Included in the Russell Microcap® Index
-
May 15, 2024
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
-
May 6, 2024
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
-
May 3, 2024
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
-
May 1, 2024
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
-
May 1, 2024
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
-
April 15, 2024
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
March 12, 2024
Aileron Therapeutics Announces CEO Transition
-
February 15, 2024
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
-
February 1, 2024
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024